Stockreport

Chinook Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for CHK-336 for Treatment of Primary Hyperoxaluria

Chinook Therapeutics, Inc.  (KDNY) 
PDF CHK-336 On Track for Phase 1 Clinical Trial Initiation in the Second Half of 2021 VANCOUVER, British Columbia and SEATTLE, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Chinook T [Read more]